New Test Launched

• Comprehensive genomic profile that interrogates the entire coding sequence of 315 cancer-related genes plus select introns from 28 genes often rearranged or altered in solid tumor cancers.
• Identifies all classes of genomic alterations, including base pair substitutions, insertions and deletions, copy number alterations and select gene rearrangements.
• Identify clinically relevant genomic alterations associated with targeted therapies
• Quantify clinical markers associated with immunotherapy response

Foundation one  Heme (hematology malignancies & sarcomas)

• Comprehensive genomic profile for hematologic cancers (leukemia, lymphoma and myeloma) and sarcomas.
• Designed to provide physicians with clinically actionable information relevant for diagnosis, risk-stratification and prognosis to guide treatment options for patients based on the genomic profile of their cancer.
• Assess routine cancer specimens for all genes that are currently known to be somatically altered in hematologic malignancies and sarcomas.
• Simultaneously detects all classes of genomic alterations, including base pair substitutions, insertions and deletions, copy number alterations and select gene rearrangements in 405 cancer-related genes.
• Also employs RNA sequencing across 265 genes to capture a broad range of gene fusions, a type of alteration that is a common driver of hematologic cancers and sarcomas.